Novartis Announced That The Preliminary Results From The Ongoing Global Phase Iii Study Stand (Nct03814746) Indicate No Statistically Significant Difference Between Crizanlizumab 5Mg/Kg Or Crizanlizumab 7.5Mg/Kg And Placebo In Annualized Rates Of Vaso-Occlusive Crises (Pain Crises) Leading To A Healthcare Visit Over The First-Year Post Randomization. These Findings Are Inconsistent With Previous Trial Results From Sustain (Nct01895361), Which Demonstrated The Superiority Of Crizanlizumab 5.0Mg/ Kg Compared To Placebo. It Is Important To Note That The Preliminary Results Do Not Suggest New Safety Concerns With Crizanlizumab. The Overall Safety Profile Of Crizanlizumab Remains Consistent With The Known Profile Of The Commercially Available 5.0Mg/Kg Dose. Since Informing Regulatory Authorities, The European Medicines Agency
